Article thumbnail

Preclinical Evaluation of Caprylic Acid-Fractionated IgG Antivenom for the Treatment of Taipan (Oxyuranus scutellatus) Envenoming in Papua New Guinea

By Mariángela Vargas, Alvaro Segura, María Herrera, Mauren Villalta, Ricardo Estrada, Maykel Cerdas, Owen Paiva, Teatulohi Matainaho, Simon D. Jensen, Kenneth D. Winkel, Guillermo León, José María Gutiérrez and David J. Williams
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2007). A new species of taipan (Elapidae: Oxyuranus) from central Australia.
  2. (1981). A study of the major Australian snake venoms in the monkey (Macaca fascicularis). II. Myolytic and haematological effects of venoms.
  3. (2010). A turbidimetric assay for the measurement of clotting times of procoagulant venoms in plasma.
  4. (1991). An epidemiological study of snake bite envenomation in Papua New Guinea.
  5. (1994). Caprylic acid fractionation of hyperimmune horse plasma: Description of a simple procedure for antivenom production.
  6. (2008). Cellular pathology induced by snake venom phospholipase A2 myotoxins and neurotoxins: common aspects of their mechanisms of action.
  7. (1980). Characterization of the prothrombin activator from the venom of Oxyuranus scutellatus scutellatus (taipan venom).
  8. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
  9. (1995). Coagulopathy following bites by the Papuan taipan (Oxyuranus scutellatus canni).
  10. (1995). Commercially available antivenoms (‘‘hyperimmune sera’’, ‘‘antivenins’’, ‘‘antisera’’) for antivenom therapy.
  11. (1989). Comparative study on coagulant, defibrinating, fibrinolytic and fibrinogenolytic activities of Costa Rican crotaline snake venoms and their neutralization by a polyvalent antivenom.
  12. (1983). Development of simple standard assay procedures for the characterization of snake venoms.
  13. (2006). Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without b-propiolactone, in the treatment of Bothrops asper bites in Colombia. Trans R Soc Trop Med Hyg
  14. (1997). Electrocardiographic abnormalities in patients bitten by taipans (Oxyuranus scutellatus canni) and other elapid snakes in Papua New Guinea. Trans Royal Soc Trop Med Hyg 91:
  15. (1995). Electrophysiological findings in patients envenomed following the bite of a Papuan Taipan Antivenom 7
  16. (2010). Endogenous thrombin potential as a novel method for the characterization of procoagulant snake venoms and the efficacy of antivenom.
  17. (1995). Failure of 3,4 diaminopyridine and edrophonium to produce significant clinical benefit in neurotoxicity following the bite of Papuan taipan (Oxyuranus scutellatus canni). Trans Royal Soc Trop Med Hyg
  18. (2003). Fractionation of equine antivenom using caprylic acid precipitation in combination with cationic ion-exchange chromatography.
  19. (2009). Gutie ´rrez JM, Leo ´n G
  20. (1989). Identification and properties of very high affinity brain membrane-binding sites for a neurotoxic phospholipase from the taipan venom.
  21. (2005). Isolation and pharmacological characterization of cannitoxin, a presynaptic neurotoxin from the venom of the Papuan taipan (Oxyuranus scutellatus canni).
  22. (1992). Isolation and physiological characterization of taicatoxin, a complex toxin with specific effects on calcium channels.
  23. (2009). Mass spectrometry analysis of the phospholipase A2 activity of snake pre-synaptic neurotoxins in cultured neurons.
  24. (1959). Modified 4-aminoantipyrine colorimetric method for phenols. Application to an acrylic monomer.
  25. (1982). Myotoxic activity of the crude venom and the principal neurotoxin, taipoxin, of the Australian taipan, Oxyuranus scutellatus.
  26. (1995). Neuromuscular effects of Papuan Taipan snake venom.
  27. (2006). Neurotoxicity and other pharmacological activities of the snake venom phospholipase A2 OS2: the N-terminal region is more important than enzymatic activity.
  28. (1987). Neurotoxins that act selectively on voltage-dependent cardiac calcium channels.
  29. (2005). Neutralization of tour Peruvian Bothrops sp snake venoms by polyvalent antivenoms produced in Peru ´ and Costa Rica: preclinical assessment.
  30. (1999). Nu ´n ˜ezV,Dı ´az
  31. (2010). Organization
  32. (2003). Papuan taipan Oxyuranus scutellatus canni envenomation in rural Papua New Guinea.
  33. (1991). Phospholipases in snake venoms and their effects on nerve and muscle.
  34. (1991). Properties of receptors for neurotoxic phospholipases A2 in different tissues.
  35. (2007). Proposal for establishment of a national antivenom unit: Submission to the Government of the Independent State of
  36. (1986). Prothrombin activation by an activator from the venom of Oxyuranus scutellatus (taipan snake).
  37. (1989). Purification of F(ab’)2 anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield.
  38. r r e zJ M ,L o m o n t eB ,C h a v e sF ,M o r e n oE ,C e r d a sL(
  39. (2010). Randomised controlled double-blind non-inferiority trial of two antivenoms for saw-scaled or carpet viper (Echis ocellatus) envenoming in Nigeria.
  40. (2005). Serine proteases affecting blood coagulation and fibrinolysis from snake venoms.
  41. (2003). Skeletal muscle degeneration induced by venom phospholipases A2: insights into the mechanisms of local and systemic myotoxicity.
  42. (1988). Snake bite in Papua New Guinea.
  43. (1995). Snake bites by the Papuan taipan (Oxyuranus scutellatus canni): paralysis, hemostatic and electrocardiographic abnormalities, and effects of antivenom.
  44. (2005). Snakebite in Papua New Guinea. In:
  45. (2005). Snakebite in southern Papua New Guinea. Postgraduate Dissertation.
  46. (2004). Snakebite mortality at Port Moresby General Hospital,
  47. (2005). Snakes across the Strait: Phylogeographic relationships in three genera of Australasian snakes (Serpentes: Elapidae: Acanthophis, Oxyuranus and Pseudechis).
  48. (1990). Standardization of assays for testing the neutralizing ability of antivenoms.
  49. (1976). Taipoxin, an extremely potent presynaptic neurotoxin from the venom of the Australian snake taipan (Oxyuranus s. scutellatus). Isolation, characterization, quaternary structure and pharmacological properties.
  50. (1999). The effects of antivenom on the in vitro neurotoxicity of venoms from the taipans Oxyuranus scutellatus, Oxyuranus microlepidotus and Oxyuranus scutellatus canni.
  51. (1995). The efficacy of antivenom in the treatment of bites by the Papuan taipan (Oxyuranus scutellatus canni). Trans Royal Soc Trop Med Hyg
  52. (1979). The lethality in mice of dangerous Australian and other snake venom.
  53. (2000). The neurotoxicity of the venom phospholipases A2, notexin and taipoxin.
  54. (2008). Unscrupulous marketing of snake bite antivenoms in Africa and Papua New Guinea: choosing the right product – ‘What’s in a name?’ Trans Royal Soc Trop Med Hyg
  55. (2010). Variations in the pharmacological profile of post-synaptic neurotoxins isolated from the venoms of the Papuan (Oxyuranus scutellatus canni) and coastal (Oxyuranus scutellatus scutellatus) taipans.
  56. (1981). World Health Organization